{
    "root": "2f836bf8-7034-db2e-e063-6394a90a3a3e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FESOTERODINE FUMARATE",
    "value": "20250304",
    "ingredients": [
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "HYPROMELLOSE 2208 (100000 MPA.S)",
            "code": "VM7F0B23ZI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FESOTERODINE FUMARATE",
            "code": "EOS72165S7",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135920"
        }
    ],
    "indications": {
        "text": "fesoterodine fumarate extended-release tablets indicated treatment : \u2022 overactive bladder ( oab ) adults symptoms urge urinary incontinence , urgency , frequency . ( 1.1 ) \u2022 neurogenic detrusor overactivity ( ndo ) pediatric patients 6 years age older weighing greater 25 kg . ( 1.2 )",
        "doid_entities": [
            {
                "text": "overactive bladder (DOID:0070355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0070355"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 oab adults : recommended starting 4 mg orally daily . based upon individual response tolerability , increase maximum 8 mg daily . ( 2.1 ) \u2022 ndo pediatric patients 6 years older : \u2022 pediatric patients weighing greater 25 kg 35 kg : recommended 4 mg orally daily . needed , may increased 8 mg orally daily . ( 2.2 ) \u2022 pediatric patients weighing greater 35 kg : recommended starting 4 mg orally daily . one week , increase 8 mg orally daily . ( 2.2 ) \u2022 adult pediatric patients renal impairment : refer full prescribing information recommended . ( 2.3 , 2.4 ) \u2022 modifications due strong cyp3a4 inhibitors : refer full prescribing information recommended . ( 2.5 ) \u2022 : swallow whole liquid . chew , divide , crush . take without food . ( 2.6 )",
        "doid_entities": [
            {
                "text": "oab (DOID:0070355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0070355"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fesoterodine fumarate extended-release tablets 4 mg light blue , oval , biconvex , film coated tablets debossed ' h ' one side 'f6 ' side . supplied follows : bottles 30 tablets ndc 31722-033-30 bottles 90 tablets ndc 31722-033-90 fesoterodine fumarate extended-release tablets 8 mg blue , oval , biconvex , film coated tablets debossed ' h ' one side 'f7 ' side . supplied follows : bottles 30 tablets ndc 31722-034-30 bottles 90 tablets ndc 31722-034-90 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "fesoterodine fumarate extended-release tablets contraindicated patients following : \u00b7 known suspected hypersensitivity fesoterodine fumarate extended-release tablets ingredients , tolterodine tartrate tablets tolterodine tartrate extended-release capsules [ pharmacology ( 12.1 ) ] . included angioedema [ ( 5.1 ) ] \u00b7 urinary retention [ ( 5.2 ) ] \u00b7 gastric retention [ ( 5.3 ) ] \u00b7 uncontrolled narrow-angle glaucoma [ ( 5.4 ) ]",
    "indications_original": "Fesoterodine fumarate extended-release tablets are indicated for the treatment of: \u2022\u00a0Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) \u2022\u00a0Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. (1.2)",
    "contraindications_original": "\u2022 OAB in Adults: The recommended starting dosage is 4 mg orally once daily. Based upon individual response and tolerability, increase to the maximum dosage of 8 mg once daily. ( 2.1 ) \u2022 NDO in Pediatric Patients 6 Years and Older: \u2022\u00a0Pediatric Patients Weighing Greater than 25 kg and up to 35 kg: The recommended dosage is 4 mg orally once daily. If needed, dosage may be increased to 8 mg orally once daily. ( 2.2 ) \u2022\u00a0Pediatric Patients Weighing Greater than 35 kg: The recommended starting dosage is 4 mg orally once daily. After one week, increase to 8 mg orally once daily. ( 2.2 ) \u2022 Adult or Pediatric Patients with Renal Impairment: Refer to the full prescribing information for recommended dosage. ( 2.3 , 2.4 ) \u2022 Dosage Modifications Due to Strong CYP3A4 Inhibitors: Refer to the full prescribing information for recommended dosage. ( 2.5 ) \u2022 Administration: Swallow whole with liquid. Do not chew, divide, or crush. Take with or without food. ( 2.6 )",
    "warningsAndPrecautions_original": "Fesoterodine fumarate extended-release tablets 4 mg are light blue, oval, biconvex, film coated tablets debossed with 'H' on one side and 'F6' on the other\u00a0side. They are supplied as follows: \n  \n                       Bottles of 30 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 31722-033-30 \n    Bottles of 90 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 31722-033-90 \n  \n                       Fesoterodine fumarate extended-release tablets 8 mg are blue, oval, biconvex, film coated tablets debossed with 'H' on one side and 'F7' on the other side.\u00a0They are supplied as follows: \n  \n                       Bottles of 30 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 31722-034-30 \n    Bottles of 90 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 31722-034-90 \n  \n                       Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Fesoterodine fumarate extended-release tablets are contraindicated in patients with any of the following: \n    \u00b7\u00a0known or suspected hypersensitivity to fesoterodine fumarate extended-release tablets or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate\u00a0extended-release capsules\n \n  [see Clinical Pharmacology (\n  \n   12.1)]\n \n  . Reactions have included angioedema\n \n  [see Warnings and Precautions\u00a0(\n  \n   5.1)]\n \n  \n                       \u00b7 urinary retention\n \n  [see Warnings and Precautions (\n  \n   5.2)]\n \n  \n                       \u00b7 gastric retention\n \n  [see Warnings and Precautions (\n  \n   5.3)]\n \n  \n                       \u00b7 uncontrolled narrow-angle glaucoma\n \n  [see Warnings and Precautions (\n  \n   5.4)]",
    "drug": [
        {
            "name": "FESOTERODINE FUMARATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135920"
        }
    ]
}